AIM ImmunoTech (AIM) Income towards Parent Company (2010 - 2026)

AIM ImmunoTech (AIM) has 17 years of Income towards Parent Company data on file, last reported at -$3.2 million in Q1 2026.

• Quarterly Income towards Parent Company rose 15.49% year-over-year to -$3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.0 million (up 32.69% YoY) and the FY2025 annual result came in at -$58.5 million, up 6.6% from the prior year.
• Income towards Parent Company steadied at -$3.2 million in Q1 2026, from -$3.2 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$2.6 million in Q3 2025 to a low of -$14.1 million in Q4 2023.
• A 5-year average of -$5.7 million and a median of -$4.9 million in 2025 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company plunged 151.04% — and 2024, when it soared 57.66%.
• Tracing AIM's Income towards Parent Company over 5 years: stood at -$5.6 million in 2022, then sank by 151.04% to -$14.1 million in 2023, then surged by 57.66% to -$6.0 million in 2024, then jumped by 45.98% to -$3.2 million in 2025, then gained by 0.31% to -$3.2 million in 2026.
• The last three Income towards Parent Company figures came in at -$3.2 million (Q1 2026), -$3.2 million (Q4 2025), and -$2.6 million (Q3 2025), per Business Quant data.